<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206788</url>
  </required_header>
  <id_info>
    <org_study_id>20170397</org_study_id>
    <secondary_id>20170333</secondary_id>
    <nct_id>NCT03206788</nct_id>
  </id_info>
  <brief_title>Losartan and Inflammation in Cystic Fibrosis</brief_title>
  <official_title>Losartan as Anti-inflammatory Therapy to Augment F508del Cystic Fibrosis Transmembrane (CFTR) Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine if a specific drug called losartan (Cozaar ®),&#xD;
      generally used to treat high blood pressure and to protect kidneys from damage in patients&#xD;
      suffering from Diabetes Mellitus, will have any effect on the nasal inflammation in patients&#xD;
      with cystic fibrosis (CF). The study will be performed at the Pulmonary Division at the&#xD;
      University of Miami, Cincinnati Children's Medical Hospital Center, University of Kansas&#xD;
      Medical Center and University of Alabama-Birmingham.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to slow enrollment and approval of the Trikafta for CF patients&#xD;
  </why_stopped>
  <start_date type="Actual">November 11, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 24, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Nasal Potential Difference (NPD) to Assess CFTR Activity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activity will be measured as the change in NPD in response to apical perfusion with 0 Cl-/isoproterenol. NPD will be measured at the nasal epithelium via a voltmeter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in NPD to Assess CaCC Activity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Potential difference of Calcium dependent Chloride Channels (CaCC) will be measured as the change in NPD on on Adenosine Triphosphate (ATP) stimulation. NPD will be measured at the nasal epithelium via a voltmeter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NPD to Assess BK Activity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Big Potassium (BK) activity will be measured as the change in NPD on Adenosine Triphosphate (ATP) stimulation. NPD will be assessed from nasal epithelium samples and analyzed via a voltmeter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Forced Expiratory Volume in 1 second (FEV1) assessed in liters will be measured using spirometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sweat Chloride Concentration</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Sweat chloride concentration will be analyzed from participant sweat samples analyzed in millimoles per liter (mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL) Scores as Assessed by the CFQ-R</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a quality of life questionnaire with a total score ranging from 0-100 with a higher score indicating increased quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cytokine Levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Nasal airway epithelial cells taken by brush will be assessed for cytokine levels including Interleukin IL-1beta, Transforming Growth Factor (TGF-beta) active and total, IL-6, IL-8 and IL-13 in pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum samples will be analyzed for High sensitivity C-Reactive Protein (hsCRP) values in mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Count Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum blood count values including white blood count (WBC) and Absolute Neutrophil Counts (ANC) will be evaluated in units/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in %PMN Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum samples will be analyzed for % Polymorphonuclear (PMN) cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SAA Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum samples will be analyzed for Serum Amyloid A (SAA) values in mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Calprotectin Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum samples will be analyzed for calprotectin values in ug/mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GM-CSF Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum samples will be analyzed for % Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF) values in pg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TGF-beta Values</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Serum samples will be analyzed for TGF-beta values in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mRNA Expression</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in messenger ribonucleic acid (mRNA) expression from nasal cells evaluated via quantitative polymerase chain reaction (qPCR) for Leucine Rich Repeating Protein 26 (LRRC26) and TGF-Beta).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Losartan Metabolites Levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in serum blood levels of Losartan and Losartan metabolites EXP3179 &amp; EXP3174.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Losartan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.</description>
    <arm_group_label>Losartan group</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>matching placebo twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CF patients homozygous for F508del and on current treatment with Orkambi™ for at least&#xD;
             3 months&#xD;
&#xD;
          -  Age &gt;12 years&#xD;
&#xD;
          -  Forced expiratory volume at one second (FEV1) &gt;/= 40% of predicted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients not willing to adhere to strict birth control (combination of two&#xD;
             methods)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of intolerance to angiotensin receptor blockers (ARBs)&#xD;
&#xD;
          -  Treatment with angiotensin converting enzyme (ACE) inhibitor&#xD;
&#xD;
          -  NPD response to zero chloride (0Cl)/isoproterenol of &gt; - 6.6 mV at screening (evidence&#xD;
             of detectable CFTR activity at baseline)&#xD;
&#xD;
          -  Regular use of NSAIDs or potassium supplementation, treatment with aliskiren, on&#xD;
             anticoagulation&#xD;
&#xD;
          -  Oral corticosteroid use within 6 weeks&#xD;
&#xD;
          -  Exacerbation requiring treatment within 6 weeks&#xD;
&#xD;
          -  Active treatment for mycobacterial infections&#xD;
&#xD;
          -  Significant hypoxemia (oxygen saturation &lt;90% on room air and rest or use of&#xD;
             continuous oxygen treatment), chronic respiratory failure by history (pCO2 &gt; 45 mmHg),&#xD;
             clinical evidence of cor pulmonale&#xD;
&#xD;
          -  Untreated arterial hypertension (systolic blood pressure &gt;140 mm Hg, diastolic blood&#xD;
             pressure &gt; 90 mmHg)&#xD;
&#xD;
          -  Blood pressure less than 90 mm Hg systolic while standing&#xD;
&#xD;
          -  Cardiac, renal (creatinine 1.5 times normal limit), hepatic (LFTs &gt; 3x normal upper&#xD;
             limit), neurological, psychiatric, endocrine or neoplastic diseases that are judged to&#xD;
             interfere with participation in study&#xD;
&#xD;
          -  Known renal artery stenosis&#xD;
&#xD;
          -  Concomitant airway disorders other than CF, such as allergic bronchopulmonary&#xD;
             aspergillosis (ABPA).&#xD;
&#xD;
          -  Subjects with prior thoracic surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Salathe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>September 24, 2020</results_first_submitted>
  <results_first_submitted_qc>October 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Matthias Salathe</investigator_full_name>
    <investigator_title>Emeritus Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03206788/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan Group</title>
          <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan Group</title>
          <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Nasal Potential Difference (NPD) to Assess CFTR Activity</title>
        <description>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activity will be measured as the change in NPD in response to apical perfusion with 0 Cl-/isoproterenol. NPD will be measured at the nasal epithelium via a voltmeter.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nasal Potential Difference (NPD) to Assess CFTR Activity</title>
          <description>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activity will be measured as the change in NPD in response to apical perfusion with 0 Cl-/isoproterenol. NPD will be measured at the nasal epithelium via a voltmeter.</description>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.1"/>
                    <measurement group_id="O2" value="1.59" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NPD to Assess CaCC Activity</title>
        <description>Potential difference of Calcium dependent Chloride Channels (CaCC) will be measured as the change in NPD on on Adenosine Triphosphate (ATP) stimulation. NPD will be measured at the nasal epithelium via a voltmeter.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NPD to Assess CaCC Activity</title>
          <description>Potential difference of Calcium dependent Chloride Channels (CaCC) will be measured as the change in NPD on on Adenosine Triphosphate (ATP) stimulation. NPD will be measured at the nasal epithelium via a voltmeter.</description>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="1"/>
                    <measurement group_id="O2" value="-5.43" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NPD to Assess BK Activity</title>
        <description>Big Potassium (BK) activity will be measured as the change in NPD on Adenosine Triphosphate (ATP) stimulation. NPD will be assessed from nasal epithelium samples and analyzed via a voltmeter.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NPD to Assess BK Activity</title>
          <description>Big Potassium (BK) activity will be measured as the change in NPD on Adenosine Triphosphate (ATP) stimulation. NPD will be assessed from nasal epithelium samples and analyzed via a voltmeter.</description>
          <units>mV</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="1"/>
                    <measurement group_id="O2" value="-5.43" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1</title>
        <description>Forced Expiratory Volume in 1 second (FEV1) assessed in liters will be measured using spirometry.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1</title>
          <description>Forced Expiratory Volume in 1 second (FEV1) assessed in liters will be measured using spirometry.</description>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.18"/>
                    <measurement group_id="O2" value="1.85" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sweat Chloride Concentration</title>
        <description>Sweat chloride concentration will be analyzed from participant sweat samples analyzed in millimoles per liter (mmol/l)</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride Concentration</title>
          <description>Sweat chloride concentration will be analyzed from participant sweat samples analyzed in millimoles per liter (mmol/l)</description>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="7.5"/>
                    <measurement group_id="O2" value="-3" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life (QoL) Scores as Assessed by the CFQ-R</title>
        <description>Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a quality of life questionnaire with a total score ranging from 0-100 with a higher score indicating increased quality of life.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life (QoL) Scores as Assessed by the CFQ-R</title>
          <description>Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a quality of life questionnaire with a total score ranging from 0-100 with a higher score indicating increased quality of life.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cytokine Levels</title>
        <description>Nasal airway epithelial cells taken by brush will be assessed for cytokine levels including Interleukin IL-1beta, Transforming Growth Factor (TGF-beta) active and total, IL-6, IL-8 and IL-13 in pg/mL.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cytokine Levels</title>
          <description>Nasal airway epithelial cells taken by brush will be assessed for cytokine levels including Interleukin IL-1beta, Transforming Growth Factor (TGF-beta) active and total, IL-6, IL-8 and IL-13 in pg/mL.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP</title>
        <description>Serum samples will be analyzed for High sensitivity C-Reactive Protein (hsCRP) values in mg/L.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP</title>
          <description>Serum samples will be analyzed for High sensitivity C-Reactive Protein (hsCRP) values in mg/L.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Count Values</title>
        <description>Serum blood count values including white blood count (WBC) and Absolute Neutrophil Counts (ANC) will be evaluated in units/uL.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Count Values</title>
          <description>Serum blood count values including white blood count (WBC) and Absolute Neutrophil Counts (ANC) will be evaluated in units/uL.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in %PMN Values</title>
        <description>Serum samples will be analyzed for % Polymorphonuclear (PMN) cells.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in %PMN Values</title>
          <description>Serum samples will be analyzed for % Polymorphonuclear (PMN) cells.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SAA Values</title>
        <description>Serum samples will be analyzed for Serum Amyloid A (SAA) values in mg/L.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SAA Values</title>
          <description>Serum samples will be analyzed for Serum Amyloid A (SAA) values in mg/L.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Calprotectin Values</title>
        <description>Serum samples will be analyzed for calprotectin values in ug/mg.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Calprotectin Values</title>
          <description>Serum samples will be analyzed for calprotectin values in ug/mg.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in GM-CSF Values</title>
        <description>Serum samples will be analyzed for % Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF) values in pg/mL.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in GM-CSF Values</title>
          <description>Serum samples will be analyzed for % Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF) values in pg/mL.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TGF-beta Values</title>
        <description>Serum samples will be analyzed for TGF-beta values in ng/mL.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TGF-beta Values</title>
          <description>Serum samples will be analyzed for TGF-beta values in ng/mL.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in mRNA Expression</title>
        <description>Change in messenger ribonucleic acid (mRNA) expression from nasal cells evaluated via quantitative polymerase chain reaction (qPCR) for Leucine Rich Repeating Protein 26 (LRRC26) and TGF-Beta).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in mRNA Expression</title>
          <description>Change in messenger ribonucleic acid (mRNA) expression from nasal cells evaluated via quantitative polymerase chain reaction (qPCR) for Leucine Rich Repeating Protein 26 (LRRC26) and TGF-Beta).</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Losartan Metabolites Levels</title>
        <description>Change in serum blood levels of Losartan and Losartan metabolites EXP3179 &amp; EXP3174.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <population>Values were not measured for this outcome for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan Group</title>
            <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Losartan Metabolites Levels</title>
          <description>Change in serum blood levels of Losartan and Losartan metabolites EXP3179 &amp; EXP3174.</description>
          <population>Values were not measured for this outcome for all participants.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Losartan Group</title>
          <description>Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nose bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pulmonary exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Matthias Salathe</name_or_title>
      <organization>Kansas University Medical Center</organization>
      <phone>913 588 6045</phone>
      <email>msalathe@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

